Yolk Sac Tumor
📧 Sign up to get email alerts when something new happens for Yolk Sac Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS other · 2026-04-17Clinical Trial Update: A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 study of BGB-B2033 alone or with tislelizumab, with or without bevacizumab, in adults with advanced or metastatic solid tumors. Indi…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors [Phase 1]
Phase 1 trial evaluating an IL-15/IL-21 armored GPC3-targeted CAR-T cell therapy for pediatric solid tumors is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors [Phase 1]
Phase 1 trial evaluating IL-15 armored glypican-3–specific CAR-T cells for solid tumors, including hepatocellular carcinoma and several pedi…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells [Phase 1]
Phase 1 pediatric trial of interleukin-15 and interleukin-21 armored glypican-3–specific CAR T cells for solid tumors, including liver-origi…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors [Phase 1]
This is an update on a Phase 1 trial of interleukin-15 armored GPC3-specific CAR-T cells for pediatric solid tumors, with results posted and…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors [Phase 1]
Phase 1 trial evaluating cytokine-armored GPC3-targeted CAR-T cells in adults with solid tumors, including hepatocellular carcinoma; the stu…
-
CLINICAL_TRIALS research · 2025-11-03Clinical Trial Update: Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells [Phase 1]
Phase 1 clinical trial evaluating GPC3-targeted CAR T cells armored with IL-15 and IL-21 for GPC3-positive solid tumors; currently recruitin…
-
CLINICAL_TRIALS research · 2025-10-24Clinical Trial Update: Molecular Epidemiology of Pediatric Germ Cell Tumors
A pediatric clinical trial by the Children's Oncology Group to study the molecular epidemiology of germ cell tumors and their histologic sub…
-
CLINICAL_TRIALS trial_result · 2025-09-19Clinical Trial Update: Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children [Phase 2, Phase 3]
A pediatric trial evaluating chemotherapy for recurrent or refractory yolk sac tumor has completed Phase 2 and Phase 3 studies.
-
CLINICAL_TRIALS trial_result · 2025-09-18Clinical Trial Update: Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor [Phase 2]
Phase 2 trial evaluating thalidomide combined with chemotherapy for relapsed or refractory yolk sac tumor and other germ cell tumors has bee…
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors [Phase 3]
This entry describes a Phase 3 trial comparing standard-dose versus high-dose combination chemotherapy with stem cell transplant for relapse…